Anne-Marie Koop

148 50. Fang Y-H, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle’s cycle. J Mol Med S.L. Archer, Medicine/Cardiology, University of Chicago, Chicago, IL 60637, United States; 2012;90:31–43. 51. Fang W, Zhao L, Xiong C-M, Ni X-H, He Z-X, He J-G, Wilkins MR. Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ United States; 2012;2:365–372. 52. Wong YY, Raijmakers P, Campen J Van, Laarse WJ Van Der, Knaapen P, Lubberink M, Ruiter G, Noordegraaf A V, Lammertsma AA. 11C-acetate clearance as an index of oxygen consumption of the right myocardium in idiopathic pulmonary arterial hypertension: A validation study using 15O-labeled tracers and PET. J Nucl Med A.A. Lammertsma, Department of Nuclear Medicine and PET Research, VU University Medical Center, 1081 BT Amsterdam, Netherlands; 2013;54:1258–1262. 53. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med E.D. Michelakis, Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada; 2013;91:1315–1327. 54. Piao L, FangY-H, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: Amaladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med S.L. Archer, Department of Medicine, Queen’s University, Etherington Hall, Kingston, ON K7L 3N6, Canada; 2013;91:1185–1197. 55. Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics N. F. Voelkel, Richmond, VA 23298, United States; 2013;45:449–461. 56. Alzoubi A, Toba M, Abe K, O’Neill KD, Rocic P, Fagan KA, McMurtry IF, Oka M. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am J Physiol - Hear Circ Physiol M. Oka, Depts. of Medicine and Pharmacology, Center for Lung Biology, Univ. of South Alabama, 3158 MSB Mobile, AL 36688-0002, United States; 2013;304:H1708–H1718. 57. Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD, Archer SL. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med 2012; 29 :1–14. 58. Gomez-Arroyo J, Mizuno S, Szczepanek K, Tassell B Van, Natarajan R, Remedios CG Dos, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Hear Fail 2013;6:136–144. 59. Friehs I, Cowan DB, Choi Y-H, Black KM, Barnett R, Nido PJ Del, Levitsky S, McCully JD. Pressure-overload hypertrophy of the developing heart reveals activation of divergent gene and protein pathways in the left and right ventricular myocardium. FASEB J I. Friehs, Cardiothoracic Surgery, Boston Children’s Hospital, Boston, United States; 2013;27.